GLORIA

GEOMAR Library Ocean Research Information Access

Ihre E-Mail wurde erfolgreich gesendet. Bitte prüfen Sie Ihren Maileingang.

Leider ist ein Fehler beim E-Mail-Versand aufgetreten. Bitte versuchen Sie es erneut.

Vorgang fortführen?

Exportieren
  • 1
    In: European Journal of Cancer, Elsevier BV, Vol. 136 ( 2020-09), p. 52-68
    Materialart: Online-Ressource
    ISSN: 0959-8049
    RVK:
    RVK:
    Sprache: Englisch
    Verlag: Elsevier BV
    Publikationsdatum: 2020
    ZDB Id: 1120460-6
    ZDB Id: 1468190-0
    ZDB Id: 82061-1
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 2
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 67, No. 23 ( 2007-12-01), p. 11234-11243
    Kurzfassung: Neuroblastoma is a heterogeneous pediatric tumor thought to arise from the embryonic neural crest. Identification of the cell responsible for propagating neuroblastomas is essential to understanding this often recurrent, rapidly progressing disease. We have isolated and characterized putative tumor-initiating cells from 16 tumors and bone marrow metastases from patients in all neuroblastoma risk groups. Dissociated cells from tumors or bone marrow grew as spheres in conditions used to culture neural crest stem cells, were capable of self-renewal, and exhibited chromosomal aberrations typical of neuroblastoma. Primary spheres from all tumor risk groups differentiated under neurogenic conditions to form neurons. Tumor spheres from low-risk tumors frequently formed large neuronal networks, whereas those from high-risk tumors rarely did. As few as 10 passaged tumor sphere cells from aggressive neuroblastoma injected orthotopically into severe combined immunodeficient/Beige mice formed large neuroblastoma tumors that metastasized to liver, spleen, contralateral adrenal and kidney, and lung. Furthermore, highly tumorigenic tumor spheres were isolated from the bone marrow of patients in clinical remission, suggesting that this population of cells may predict clinical behavior and serve as a biomarker for minimal residual disease in high-risk patients. Our data indicate that high-risk neuroblastoma contains a cell with cancer stem cell properties that is enriched in tumor-initiating capacity. These cells may serve as a model system to identify the molecular determinants of neuroblastoma and to develop new therapeutic strategies for this tumor. [Cancer Res 2007;67(23):11234–43]
    Materialart: Online-Ressource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Sprache: Englisch
    Verlag: American Association for Cancer Research (AACR)
    Publikationsdatum: 2007
    ZDB Id: 2036785-5
    ZDB Id: 1432-1
    ZDB Id: 410466-3
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 3
    Online-Ressource
    Online-Ressource
    American Association for Cancer Research (AACR) ; 2016
    In:  Cancer Research Vol. 76, No. 5_Supplement ( 2016-03-01), p. PR06-PR06
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 76, No. 5_Supplement ( 2016-03-01), p. PR06-PR06
    Kurzfassung: Recently, we have presented the genomic landscape of 87 neuroblastoma tumors. This cohort has been extended to include 108 tumor/normal pairs of all INSS stages. As recurrent somatic mutations are rare in this cancer and enhancer hijacking has been demonstrated in medulloblastoma, we hypothesized that recurrent structural variations, possibly intergenic, could be identified in our neuroblastoma cohort. Methods: Whole genome sequencing was performed on a total of 108 tumor/lymphocyte DNA samples using Complete Genomics technology. Somatic structural variations were identified and analyzed for recurrent locations. Sequence coverage based CGH break analyses, mRNA expression analyses, telomere length analyses as well as super-enhancer proximity analyses were performed. Results: For each 1 Mb region in the genome, we calculated the number of tumors with one or more structural events. The second-most frequently affected region after MYCN was located on chromosome 5 where breakpoints centered round the TERT locus in 17/75 of the high stage tumors (23%). TERT was the only gene in the vicinity with a significantly increased expression in the rearranged cases as compared to the normal cases (p=8.51x10-5, Wilcoxon Ranksum test). Most of the TERT rearrangements occurred in a region 6-30 kb upstream of the gene. 12 of the rearrangements were resolved by paired-end analysis. We identified neuroblastoma-specific super-enhancers in seven of the translocation partners, which is a significant enrichment compared to randomly generated breaks (p & lt;0.003). Telomere restriction fragment analysis showed increased telomere lengths for rearranged cases, confirming increased telomere repeat counts in the corresponding sequence data. TERT rearrangements were significantly associated with poor prognosis (p=0.04 Logrank test) and almost mutually exclusive with MYCN amplification and ATRX defects. In a multivariate Cox regression analysis all 3 showed independent significance. Kaplan Meier analysis showed that each of the MYCN, TERT and ATRX groups had a significantly poorer outcome than the remaining tumors. Conclusions: We conclude that TERT rearrangements form the second-most frequent gene defect in neuroblastoma, after MYCN. TERT defects are almost mutually exclusive with ATRX and MYCN defects, and each of them identify a separate group of neuroblastoma at very high risk. These tumors have elevated TERT expression due to rearrangement of the upstream 30 kb or downstream 40 kb regions and in over half of the informative breakpoints, TERT was ostensibly activated by hijacking a super-enhancer. Pharmacological inhibition of TERT might in future improve the outcome for this patient group. This abstract is also presented as Poster A40. Citation Format: Jan Koster, Linda J. Valentijn, Danny A. Zwijnenburg, Nancy E. Hasselt, Peter G. van Sluis, Max M. van Noesel, Rani E. George, Godelieve A. Tytgat, Jan J. Molenaar, Rogier Versteeg. TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors. [abstract]. In: Proceedings of the AACR Special Conference on Advances in Pediatric Cancer Research: From Mechanisms and Models to Treatment and Survivorship; 2015 Nov 9-12; Fort Lauderdale, FL. Philadelphia (PA): AACR; Cancer Res 2016;76(5 Suppl):Abstract nr PR06.
    Materialart: Online-Ressource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Sprache: Englisch
    Verlag: American Association for Cancer Research (AACR)
    Publikationsdatum: 2016
    ZDB Id: 2036785-5
    ZDB Id: 1432-1
    ZDB Id: 410466-3
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 4
    In: Nature Genetics, Springer Science and Business Media LLC, Vol. 47, No. 12 ( 2015-12), p. 1411-1414
    Materialart: Online-Ressource
    ISSN: 1061-4036 , 1546-1718
    RVK:
    Sprache: Englisch
    Verlag: Springer Science and Business Media LLC
    Publikationsdatum: 2015
    ZDB Id: 1494946-5
    SSG: 12
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 5
    Online-Ressource
    Online-Ressource
    American Association for Cancer Research (AACR) ; 2015
    In:  Clinical Cancer Research Vol. 21, No. 21 ( 2015-11-01), p. 4747-4749
    In: Clinical Cancer Research, American Association for Cancer Research (AACR), Vol. 21, No. 21 ( 2015-11-01), p. 4747-4749
    Kurzfassung: Bellini and colleagues demonstrate the importance of next-generation sequencing to uncover subclonal anaplastic lymphoma kinase (ALK) mutations in neuroblastoma. Although the significance of these subclonal aberrations is not yet understood, deep sequencing could identify patients whose tumors may respond to ALK inhibitors. Clin Cancer Res; 21(21); 4747–9. ©2015 AACR. See related article by Bellini et al., p. 4913
    Materialart: Online-Ressource
    ISSN: 1078-0432 , 1557-3265
    RVK:
    Sprache: Englisch
    Verlag: American Association for Cancer Research (AACR)
    Publikationsdatum: 2015
    ZDB Id: 1225457-5
    ZDB Id: 2036787-9
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 6
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 71, No. 8_Supplement ( 2011-04-15), p. 4296-4296
    Kurzfassung: Neuroblastoma is the most common extracranial solid tumor in children and originates during development of the peripheral sympathetic nervous system. Advanced-stage disease and a poor outcome are associated with amplification of the MYCN oncogene, often in combination with mutational activation or amplification of another oncogene ALK (anaplastic lymphoma kinase), suggesting that they cooperate in neuroblastoma pathogenesis. To investigate this possibility, we generated a transgenic zebrafish model of neuroblastoma in which human MYCN is expressed under the control of the dopamine-beta-hydroxylase promoter, and show that the resultant tumors recapitulate childhood neuroblastomas histologically, immunohistochemically, and ultrastructurally. Surprisingly, the tumors arise from a subpopulation of neuroblasts that migrate into the adrenal analogue (interrenal gland) in the zebrafish after organogenesis is complete. Coexpression of activated ALK with MYCN markedly increased the frequency of neuroblastoma and accelerated the time of onset, providing conclusive evidence for synergistic interplay between these two oncogenes in neuroblastoma pathogenesis. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4296. doi:10.1158/1538-7445.AM2011-4296
    Materialart: Online-Ressource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Sprache: Englisch
    Verlag: American Association for Cancer Research (AACR)
    Publikationsdatum: 2011
    ZDB Id: 2036785-5
    ZDB Id: 1432-1
    ZDB Id: 410466-3
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 7
    Online-Ressource
    Online-Ressource
    American Association for Cancer Research (AACR) ; 2011
    In:  Cancer Research Vol. 71, No. 8_Supplement ( 2011-04-15), p. 4757-4757
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 71, No. 8_Supplement ( 2011-04-15), p. 4757-4757
    Kurzfassung: Activating mutations in the anaplastic lymphoma receptor tyrosine kinase gene (ALK) have been identified in neuroblastoma and represent a novel therapeutic target in this childhood tumor of the sympathetic nervous system. The ALK-F1174L mutation, in particular, occurs at a higher frequency in tumors with MYCN gene amplification, is associated with a worse prognosis and with resistance to pharmacologic ALK inhibitors in adults with ALK-translocated cancers. To investigate the role of mutated ALK in MYCN-driven neuroblastoma, we generated transgenic mice that overexpress ALK-F1174L in neural crest-derived cells under the control of the tyrosine hydroxylase (TH) promoter, and performed genetic crosses against TH-MYCN transgenic mice. Doubly transgenic TH-ALK-F1174L/TH-MYCN animals developed aggressive tumors of the adrenal glands and abdominal and thoracic sympathetic ganglia, with 100% penetrance and a very short latency (31 days). In contrast, TH-MYCN littermates failed to develop tumors by this time. Furthermore, TH-ALK-F1174L hemizygote or homozygote animals failed to initiate tumors in the absence of MYCN expression. On histologic examination, ALK-F1174L/MYCN tumors were stroma poor and displayed undifferentiated small round blue cells with numerous apoptotic figures and scattered mitoses, and exhibited strong expression of both MYCN and aberrant ALK-F1174L transcripts and protein. Taken together, our studies demonstrate that the ALK-F1174L mutation plays a potent and significant role in the genesis of neuroblastoma, cooperating with MYCN to drive tumor formation. To our knowledge, this is the first mouse model available for investigations into the role of mutant ALK in neuroblastoma, especially its interaction with MYCN, and should provide a valuable new tool for development of ALK-targeted therapeutics in neuroblastoma. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4757. doi:10.1158/1538-7445.AM2011-4757
    Materialart: Online-Ressource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Sprache: Englisch
    Verlag: American Association for Cancer Research (AACR)
    Publikationsdatum: 2011
    ZDB Id: 2036785-5
    ZDB Id: 1432-1
    ZDB Id: 410466-3
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 8
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 73, No. 8_Supplement ( 2013-04-15), p. 5037-5037
    Kurzfassung: In neuroblastoma, mutations in the anaplastic lymphoma kinase (ALK) tyrosine kinase gene have been identified in 8-10 % of primary tumors. The most common and potent ALK mutation, ALKF1174L, leads to the constitutive activation of the ALK protein and is associated preferentially with MYCN amplification, a markedly poorer prognosis, and confers resistance to the promising ALK inhibitor crizotinib. The development of more efficacious ALK inhibitors will benefit from non-invasive imaging strategies for the rapid identification of children with high-risk ALK-expressing or mutated neuroblastoma. Intrinsic susceptibility magnetic resonance imaging (IS-MRI) data was acquired from tumors arising in TH-ALKF1174L/TH-MYCN and TH-MYCN mice, two genetically engineered mouse model of high-risk neuroblastoma. The native MRI transverse relaxation rate R2*, an imaging biomarker sensitive to the concentration of paramagnetic deoxyhemoglobin, and changes in R2* induced with 100% oxygen inhalation, were quantified. Tumors in the TH-ALKF1174L/TH-MYCN mice demonstrated significantly (p & lt;0.0001) slower native R2* rates (61 ± 3s−1, n=23) than tumors in the TH-MYCN mice (101 ± 6s−1, n=21). With hyperoxic challenge, the TH-ALKF1174L/TH-MYCN mice demonstrated a significantly (p & lt;0.0001) lower and negligible ΔR2*oxygen-air (-3 ± 1s−1, n=10) compared with tumors in TH-MYCN mice (-26 ± 3s−1, n=12). A sensitivity of 90% and a specificity of 81% for native R2*, and a sensitivity of 90% and a specificity of 94% for hyperoxia-induced ΔR2* was determined. Histological correlates revealed a significantly (p & lt;0.05) higher uptake of the perfusion marker Hoechst 33342, and the presence of large hemorrhagic blood lakes filled with stagnant deoxygenated erythrocytes, in tumors within the TH-MYCN mice, but not the TH-ALKF1174L/TH-MYCN model. Together these corroborate the IS-MRI findings (relatively fast native R2* and significant ΔR2*, indicative of vascular instability, in tumors in the TH-MYCN mice). IS-MRI provides a robust method to discriminate and identify TH-MYCN transgenic mice harboring the ALKF1174L mutation based on a stark differential vascular phenotype, which may impact on impaired drug delivery. IS-MRI is suitable for the scanning of young children, and quantitation of native R2* easily incorporated into existing pediatric clinical imaging protocols. This approach could provide a robust and rapid indicator of ALK genotypic status of the tumor, enabling the early identification of children with ultra high-risk neuroblastoma at the time of diagnosis. Citation Format: Yann Jamin, Laura Glass, Albert Hallsworth, Rani E. George, Dow-Mu Koh, Andrew D.J. Pearson, Louis Chesler, Simon P. Robinson. Intrinsic susceptibility magnetic resonance imaging identifies tumors with ALKF1174L mutation in transgenic murine models of high-risk neuroblastoma. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 5037. doi:10.1158/1538-7445.AM2013-5037
    Materialart: Online-Ressource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Sprache: Englisch
    Verlag: American Association for Cancer Research (AACR)
    Publikationsdatum: 2013
    ZDB Id: 2036785-5
    ZDB Id: 1432-1
    ZDB Id: 410466-3
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 9
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 72, No. 8_Supplement ( 2012-04-15), p. 2935-2935
    Kurzfassung: Mutations in the anaplastic lymphoma kinase (ALK) receptor represent an important therapeutic target in neuroblastoma. The most frequently occurring somatic mutation, ALK F1174L, is sensitive to the ALK inhibitor crizotinib only at higher doses in vitro, and not at all in in vivo. Moreover, ALK F1174L mediates acquired resistance to crizotinib in ALK-rearranged cancers, posing a therapeutic challenge in these diseases. To identify critical components of ALK F1174L-associated signaling pathways that contribute to neuroblastoma cell survival and whose simultaneous inhibition with ALK F1174L could increase sensitivity to crizotinib, we exposed neuroblastoma cell lines expressing ALK F1174L (Kelly and SHSY-5Y) to crizotinib (at treatment doses and exposures times titrated to abolish ALK phosphorylation, but in the absence of any detectable commitment to apoptosis), and compared their “ALK-inactive” gene expression signatures with vehicle-treated control cells in which the ALK F1174L signature remained “active”. We noted differential expression of genes involved in the PI3K/AKT/mTOR pathway in cells in which ALK F1174L was inhibited with crizotinib, with downregulation of AKT1, 2 and 3 and elevated expression of mTOR. Immunoblotting confirmed that downregulation of pALK upon exposure to crizotinib was accompanied by downregulation of pAKT473, with unchanged or elevated pRPS6. To test the possibility that the cytotoxicity of crizotinib could be enhanced by simultaneous inhibition of this ALK-driven pathway, we tested crizotinib in combination with the ATP-competitive mTOR inhibitor, Torin2, both in cell lines and in xenograft models of neuroblastoma expressing ALK F1174L. Treatment with crizotinib had no standalone activity as demonstrated by lack of effects on tumor volume or survival. Treatment with Torin2 significantly suppressed tumor growth, but this did not translate into a prolongation of survival. Combined treatment with Torin2 and crizotinib resulted in significant attenuation of tumor growth (p & lt;0.001), and prolongation of survival in comparison to control animals, as well as single agent treatment with either Torin2 or crizotinib. RPS6 remained phosphorylated in neuroblastoma xenografts of mice treated exclusively with crizotinib but was downregulated in cells treated with Torin 2, and in those treated with the combination. Together, these results suggest that single agent treatment with crizotinib at standard doses is less efficacious due to persistent activation of mTOR signaling and that mTOR pathway inhibition should augment the activity of crizotinib in the treatment of patients with ALK F1174L-expressing neuroblastomas and may even delay the onset of resistance in ALK-rearranged cancers in which this pathway is activated. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2935. doi:1538-7445.AM2012-2935
    Materialart: Online-Ressource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Sprache: Englisch
    Verlag: American Association for Cancer Research (AACR)
    Publikationsdatum: 2012
    ZDB Id: 2036785-5
    ZDB Id: 1432-1
    ZDB Id: 410466-3
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 10
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 76, No. 2_Supplement ( 2016-01-15), p. PR04-PR04
    Kurzfassung: Cyclin-dependent kinases (CDKs) with primary roles in transcription regulation are emerging as tractable therapeutic targets in cancers driven by the aberrant expression of oncogenic transcription factors. Our goal is to disrupt the myriad and pleomorphic features of oncogenic MYC through inhibiting CDKs involved in its transcriptional amplifier role. CDK7 participates in transcription initiation by phosphorylating the carboxy-terminal domain (CTD) of RNA polymerase (Pol) II and also functions as a CDK-activating kinase, while CDK12 functions in transcription elongation and RNA processing. Using a novel covalent CDK7 inhibitor, THZ1, we demonstrated striking activity and selectivity in neuroblastoma (NB) cells driven by high MYCN expression. This response translated to significant tumor regression in a mouse model of high-risk NB, without introducing discernible toxicity. We determined that this effect was associated with global inhibition of MYCN-dependent transcriptional amplification. THZ1 led to preferential downregulation of Pol II occupancy at super-enhancer-associated genes, including MYCN and other master transcription factors critical to neuronal development such as PHOX2B, GATA2, and DBH. Similarly, inhibition of CDK12 activity using a novel, first-in-class small molecule inhibitor, THZ-5-31-1, resulted in potent antitumor activity in MYCN-overexpressing NB cells. THZ-5-31-1 doses sufficient to induce PARP cleavage did not lead to significant inhibition of global transcription elongation. Rather, cytotoxicity was associated with preferential downregulation of RNA processing factors and a higher percentage of immature mRNA transcripts. Together, these results suggest that transcriptional CDK inhibitors, by affecting different aspects of the transcription machinery, may inhibit the growth of cancers driven by oncogenic transcription factors such as MYC. Citation Format: Malgorzata Krajewska, Nathan F. Moore, Edmond Chipumuro, Tinghu Zhang, Eugenio Marco, Clark Hatheway, Bandana Sharma, Nicholas Kwiatkowski, Guo-Cheng Yuan, Richard A. Young, Nathanael S. Gray, Rani E. George. Targeting super-enhancer driven oncogene transcription through cyclin-dependent kinase inhibitors. [abstract]. In: Proceedings of the AACR Special Conference on Chromatin and Epigenetics in Cancer; Sep 24-27, 2015; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2016;76(2 Suppl):Abstract nr PR04.
    Materialart: Online-Ressource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Sprache: Englisch
    Verlag: American Association for Cancer Research (AACR)
    Publikationsdatum: 2016
    ZDB Id: 2036785-5
    ZDB Id: 1432-1
    ZDB Id: 410466-3
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
Schließen ⊗
Diese Webseite nutzt Cookies und das Analyse-Tool Matomo. Weitere Informationen finden Sie hier...